Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

BRISTOL-MYERS Aktie

 >BRISTOL-MYERS Aktienkurs 
57.4 EUR    -2.0%    (TradegateBSX)
Ask: 57.63 EUR / 100 Stück
Bid: 57.4 EUR / 100 Stück
Tagesumsatz: 3019 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>BRISTOL-MYERS Performance
1 Woche: +0,2%
1 Monat: +0,6%
3 Monate: +18,3%
6 Monate: +7,5%
1 Jahr: +43,0%
laufendes Jahr: +24,6%
>BRISTOL-MYERS Aktie
Name:  BRISTOL-MYERS SQUIBBDL-10
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1101221083 / 850501
Symbol/ Ticker:  BRM (Frankfurt) / BMY (NYSE)
Kürzel:  FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY
Index:  S&P500
Webseite:  https://www.bms.com/
Profil:  Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematolo..
>Volltext..
Marktkapitalisierung:  117979.28 Mio. EUR
Unternehmenswert:  147751.27 Mio. EUR
Umsatz:  42458.35 Mio. EUR
EBITDA:  16567.34 Mio. EUR
Nettogewinn:  8010.94 Mio. EUR
Gewinn je Aktie:  3.93 EUR
Schulden:  38883.54 Mio. EUR
Liquide Mittel:  7527.63 Mio. EUR
Operativer Cashflow:  11031.66 Mio. EUR
Bargeldquote:  0.59
Umsatzwachstum:  6.37%
Gewinnwachstum:  89.62%
Dividende je Aktie:  2.16 EUR
Dividendenrendite:  3.75%
Dividendenschätzung:  3.77%
Div. Historie:  02.07.26 - 0.550557€
02.04.26 - 0.546777€
>weitere anzeigen...
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 29.060 Euro.
Suchwörter:  BRISTOL-MYERS, BRISTOL MYERS
Letzte Datenerhebung:  06.09.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 2042.71 Mio. St.
Frei handelbar: 99.68%
Leerverk. Aktien: 2.24%
Rückkaufquote: -
Mitarbeiter: 32500
Umsatz/Mitarb.: 1.28 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: -1.11%
Bewertung:
KGV: 14.56
KGV lG: 9.68
KUV: 2.77
KBV: 6.05
PEG-Ratio: 0.18
EV/EBITDA: 8.92
Rentabilität:
Bruttomarge: 66.64%
Gewinnmarge: 18.87%
Operative Marge: 32.35%
Managementeffizenz:
Gesamtkaprendite: 10.18%
Eigenkaprendite: 46.7%
 >Anleihen 
>Peer Group
Gesundheit, Neurologische Erkrankungen/ Schlaganfälle, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie
 
05.09.26 - 01:15
 Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today (Zacks)
 
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day....
04.09.26 - 22:45
 Will Camzyos′ Long-Term Benefits Strengthen BMY′s Growth Outlook? (Zacks)
 
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion....
04.09.26 - 00:01
 Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects (WSJ EN)
 
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky....
03.09.26 - 15:06
 Bristol-Myers Squibb Company: Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds (Accesswire)
 
Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospital ALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.orgA trailbla......
29.08.26 - 17:01
 Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors (Fool)
 
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force....
27.08.26 - 18:15
 Can Camzyos′ Growth Offset Bristol Myers′ Patent Pressures? (Zacks)
 
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs....
27.08.26 - 02:01
 Insiderhandel: SVP and Controller verkauft Aktien von Bristol-Myers Squibb Company im Wert von 33750 USD (Insiderkauf)
 
Holzer, Phil M. - Vorstand - Tag der Transaktion: 2026-08-25...
25.08.26 - 18:45
 Bristol Myers reportedly exits Cellares pact prompting restructuring at cell therapy maker (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.08.26 - 17:03
 BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy (PR Newswire)
 
Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical......
21.08.26 - 18:15
 Can Eliquis Cushion Bristol Myers′ Legacy Portfolio Erosion? (Zacks)
 
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook....
20.08.26 - 16:42
 Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO (24/7 Wall St.)
 
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third....
19.08.26 - 14:36
 Hematogenix′s MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb′s ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma (PR Newswire)
 
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials. TINLEY PARK, Ill., Aug. 19, 2026......
19.08.26 - 14:12
 Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play (24/7 Wall St.)
 
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why....
18.08.26 - 16:24
 3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now (Fool)
 
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations....
16.08.26 - 13:36
 Hematogenix′s Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb′s ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma (PR Newswire)
 
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials. TINLEY PARK, Ill., Aug. 14, 2026......
14.08.26 - 22:45
 Can BMY′s First CELMoD Approval Support Its Growth Strategy? (Zacks)
 
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates....
14.08.26 - 22:00
 AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power....
14.08.26 - 04:36
 Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? (Fool)
 
There's a good reason why AstraZeneca tanked when merger rumors hit the Street....
13.08.26 - 22:48
 Atrium Therapeutics Reports Second Quarter 2026 Financial Results (PR Newswire)
 
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA)......
13.08.26 - 19:48
 Lawsuit against Bristol Myers over delayed cancer drug is revived (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Philosophen verderben die Sprache, Poeten die Logik, und mit dem Menschenverstand kommt man durchs Leben nicht mehr. - Friedrich Johann Christoph Schiller
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!